Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Emma Guttman‐Yassky(Rockefeller University), Mark Lebwohl(Icahn School of Medicine at Mount Sinai)
Cited by 334
Related Papers
Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune Abnormalities
|Journal of Allergy and Clinical Immunology|2011|457